Guest Editors
Dr. Bizzarri Francesco Pio
Email: francescopiobizzarri1994@gmail.com
Affiliation: 1. Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
2. Department of Urology, Ospedale Isola Tiberina Gemelli Isola, Rome, Italy
Homepage:
Research Interests: robotic surgery in urological disease, uro-oncology, prostate cancer, bladder cancer, kidney cancer, urothelial cancer
Dr. Pierluigi Russo
Email: pierluigi92.russo@gmail.com
Affiliation: Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Homepage:
Research Interests: urological disease, uro-oncology
Summary
Urothelial carcinoma (UC) remains one of the most prevalent and challenging malignancies in urology. In recent years, growing evidence has highlighted the crucial role of inflammation in tumor progression, immune evasion, and response to therapy. Various inflammatory indices, such as the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Systemic Immune-Inflammation Index (SII), have been associated with prognosis, therapeutic response, and patient stratification in UC.
This Special Issue aims to explore the latest advancements in the use of inflammatory biomarkers in UC, from risk assessment and early diagnosis to treatment response prediction and personalized therapeutic strategies. By integrating inflammation-based markers with molecular and genetic profiling, we hope to refine patient selection for immunotherapy, chemotherapy, and targeted treatments, ultimately paving the way for a more individualized approach to urothelial carcinoma management.
Topics of Interest:
· The role of systemic inflammatory indices (NLR, PLR, SII) in UC prognosis
· Inflammation-driven molecular pathways in bladder cancer progression
· Predictive value of inflammatory markers for response to immunotherapy (e.g., checkpoint inhibitors)
· Integration of inflammation-based scores with genomic and transcriptomic data
· The impact of chronic inflammation on UC recurrence and progression
· Novel therapeutic approaches targeting inflammation in urothelial carcinoma
· Integration of Machine Learning in UC diagnosis and prognosis
· Novel perspective in Urothelial cancer that can improve or modify therapeutic strategies
With this Special Issue, we aim to provide a comprehensive overview of the interplay between inflammation and UC, fostering translational research and clinical applications that can enhance precision medicine in urology.
Keywords
bladder cancer, urothelial cancer, inflammatory factors, machine learning, novel therapeutic approaches.
Login
Register
Submit a Paper
Propose a Special lssue